Eltrombopag is a TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as cMpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production.

Immune Thrombocytopenia (ITP) in adults and children ≥6 years who did not respond to other treatments.

Thrombocytopenia associated with chronic hepatitis C, to enable initiation and continuation of interferon-based therapy.

Severe Aplastic Anemia (SAA) in adults with inadequate response to immunosuppressive therapy.

ITP: 36 mg once daily (adults/pediatric ≥6), reduced to 18 mg for hepatic impairment or East-/Southeast-Asian ancestry.

Hepatitis C: 18 mg once daily.

SAA: 36 mg once daily, reduced to 18 mg if liver-impaired or East-/Southeast-Asian.

Most Common (≥20% in any indication):

• Anemia, fatigue, headache, diarrhea, ALT increase, pyrexia, cough.

ITP-Specific Reactions:

• Adults: Nausea, vomiting, UTI, ALT/AST elevations, rash.
• Pediatrics: Upper respiratory tract infections, nasopharyngitis, diarrhea, ALT/AST elevations.

SAA-Specific:

• Nausea (33%), fatigue (28%), cough (23%), diarrhea (21%).

None

Hepatic risk: Elevated ALT/AST, bilirubin.

Progression of MDS to AML: Increased risk when combined with azacitidine.

Thromboembolic events: Especially portal vein thrombosis.

Cataracts: Observed in trials and animal studies—eye monitoring recommended.